Tom Casey, a successful entrepreneur in the AI and healthcare space, delivered an informative presentation to the Fallbrook Parkinson's Group, highlighting a groundbreaking treatment for degenerative diseases.
The focal point of his presentation to a packed crowd at the Wellness Center was the utilization of young Fresh Frozen Plasma (yFFP®) as a transformative treatment option that has proven effective to reverse diseases such as diabetes, Parkinson's, and Alzheimer's. In his PowerPoint presentation, Casey showed how aging is slowed with the use of young plasma.
Moreover, Casey stressed that plasma is an organic and naturally renewable resource. Healthful to donate at any adult age, plasma contains a complex mixture of over 10,500 individual proteins, 5,000 different peptides, 45 cytokines, 1.84 billion exosomes per ml, 50 different sex-specific hormones, enzymes, and minerals, making it the most versatile component of human blood.
Additionally, the infrastructure for collecting plasma for therapeutic, surgical or pharmaceutical use is already in place through 3,000 blood banks and plasma collection centers, making implementation feasible at a local level, nationwide.
"Plasma has been used for over 100 years," said Casey. "Serum, now known as convalescent plasma, was awarded the first Nobel Prize in Medicine in 1901. Plasma became an approved biologic in 1938 and the medical use of plasma is legal. Since World War II, roughly 20% of all plasma collected in the United States is from young donors."
He added that the U.S. is a major provider of plasma to the rest of the world, with global exports of plasma exceeding global exports of airplanes in 2016.
Casey reported that at least one person in Fallbrook has had a transfusion of 2.5-liters of young plasma and it has provided a significant reduction in that individual's biologic rate of aging, which is directly correlated to length and quality of life. The Village News is reaching out to this person for an interview.
Sex-identified plasma from a 18-25 year old volunteer donor is about $5,000 a liter, and not presently reimbursed. Casey owns the world's first and only fully accredited blood bank that exclusively collects yFFP from the students at Texas State University in San Marcos.
Currently, yFFP is only available for prescription in Texas so, at this time, travel and practitioner testing, and treatment charges will apply. If someone doesn't have the finances to receive young plasma transfusions, the collection-detoxification option was something that Casey stressed everyone could do.
It is now known that the simple act of donating plasma is detoxifying to the donor and regenerative at any age, but, "if individuals start donating their plasma when they are young and then continue throughout their life on a weekly basis, not only is their plasma life-giving for older people with degenerative diseases, or those undergoing surgeries, Berkeley has published that the plasma dilution provided by donations also promotes longevity and neurogenesis, even in the young, helping to stop or reverse some of the negative effects of bad eating habits and lifestyle choices."
Although the San Diego Blood Bank emphasizes collecting red cells and platelets for hospital surgeries, and not plasma, BioLife Plasma Services in Vista and San Marcos are local sites where people could donate their plasma, and if accepted as donors, be paid for it. While blood banks collect for human use, pharmaceutical companies like BioLife use the plasma they collect as the raw material to manufacture important medicines.
"For example," Casey stated, "we currently have over 35 million suffering from diabetes in the U.S. If people would utilize the option of frequent paid plasma donations when they are young, we could save billions of dollars in national healthcare costs by stopping or reversing the now relentless advancement of chronic diseases such as metabolic disorders, renal disease, systemic inflammation, heart disease and neurodegeneration."
Medicare spending for kidney failure patients is at $35 billion in 2016. They are 1% of the U.S. Medicare population but account for roughly 7% of the Medicare budget. Hemodialysis care costs the Medicare system an average of $90,000 per patient annually in the United States, for a total of $28 billion.
During his presentation, Casey emphasized the significant impact of aging on individuals and the healthcare system as a whole.
Casey highlighted the alarming fact that chronic conditions, responsible for 90% of the nation's $3.8 trillion in annual healthcare expenditures, continue to exert a substantial burden on the healthcare system. Furthermore, national health expenditures are predicted to reach an astonishing $5 trillion by 2025, further straining the economy. Aging into Medicare is anticipated to be a significant contributing factor to this exponential growth.
Drawing upon extensive research, Casey emphasized the use of yFFP in addressing age-related conditions. He shared insights from documented, IRB authorized human trials, which demonstrated the safety and efficacy of using yFFP as a regenerative therapy. These studies involved the intravenous and/or plasma-exchange administration within 30-days of 2 to 3 liters of yFFP. Most commonly, the course of therapy is administered over two days.
According to Casey, understanding the plasma proteome has revealed that aging follows a programmed trajectory, with significant changes occurring at specific points in an individual's life. By infusing or exchanging plasma from sex-matched young donors aged 18 to 25, that program becomes "bio-hacked" as their body's cells respond by actively regenerating and restoring lost function, mirroring their youthful behavior.
It appears to be a win-win for the donor, the receiver, and the entire healthcare system and taxpayers. "Plasma is our golden gift from Mother Nature and the closest thing we have to a fountain of youth," said Casey.